H19 long noncoding RNA in maternal obesity-driven metabolic programming

Area of Science:

• Reproductive biology
• Developmental biology
• Metabolic disease research

Background:

• Maternal obesity during pregnancy is linked to adverse offspring outcomes.
• Obesity disrupts embryonic development, muscle formation, and metabolic regulation.
• Altered H19 gene expression is implicated in these developmental disruptions.

Purpose of the Study:

• To investigate the impact of maternal obesity on H19 expression and offspring development.
• To examine the potential of metformin as an intervention during early pregnancy.
• To understand the role of AMP-activated protein kinase (AMPK) and epigenetics in mediating these effects.

Main Methods:

• Maternal obesity models were established.
• H19 expression levels were analyzed in placental and embryonic tissues.
• Offspring development, muscle formation, and metabolic parameters were assessed.
• Metformin treatment effects were evaluated, including AMPK activation and epigenetic modifications.

Main Results:

• Maternal obesity led to altered H19 expression and impaired embryonic development.
• Offspring exhibited signs of muscle development issues, fibrogenesis, and metabolic dysfunction.
• Metformin treatment in early pregnancy modulated placental H19 expression.
• Metformin intervention positively influenced offspring metabolic health, potentially via AMPK and epigenetic pathways.

Conclusions:

• Maternal obesity poses significant risks to offspring development and long-term metabolic health.
• Early pregnancy metformin administration shows promise in mitigating adverse effects.
• Targeting placental H19 expression through AMPK and epigenetic mechanisms is a potential therapeutic strategy.